Prometheus Biosciences - RXDX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $107.80
  • Forecasted Upside: -6.07%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$114.77
▼ -1.35 (-1.16%)

This chart shows the closing price for RXDX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prometheus Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RXDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RXDX

Analyst Price Target is $107.80
▼ -6.07% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Prometheus Biosciences in the last 3 months. The average price target is $107.80, with a high forecast of $181.00 and a low forecast of $51.00. The average price target represents a -6.07% upside from the last price of $114.77.

This chart shows the closing price for RXDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Prometheus Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/5/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/3/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2022Credit Suisse GroupBoost TargetOutperform$59.00 ➝ $142.00Low
12/8/2022Wells Fargo & CompanyBoost Target$71.00 ➝ $164.00Low
12/8/2022BTIG ResearchBoost TargetBuy$74.00 ➝ $181.00Low
12/8/2022OppenheimerBoost TargetOutperform$61.00 ➝ $125.00Low
12/7/2022Royal Bank of CanadaBoost Target$66.00 ➝ $111.00Low
12/7/2022Piper SandlerBoost Target$67.00 ➝ $114.00N/A
11/1/2022Stifel NicolausBoost TargetBuy$50.00 ➝ $55.00Low
10/4/2022OppenheimerBoost TargetOutperform$50.00 ➝ $65.00Low
10/4/2022Royal Bank of CanadaBoost Target$61.00 ➝ $66.00Low
10/3/2022BTIG ResearchBoost TargetBuy$62.00 ➝ $74.00Low
8/29/2022Wells Fargo & CompanyBoost TargetOverweight$51.00 ➝ $71.00Low
8/28/2022Piper SandlerBoost TargetOverweight$53.00 ➝ $67.00Low
8/12/2022Royal Bank of CanadaBoost Target$45.00 ➝ $61.00Low
8/12/2022Credit Suisse GroupBoost TargetOutperform$52.00 ➝ $59.00Low
8/12/2022SVB LeerinkBoost TargetOutperform$55.00 ➝ $60.00Low
7/27/2022GuggenheimBoost TargetOutperform$75.00Low
7/20/2022The Goldman Sachs GroupInitiated CoverageBuy$51.00Low
6/10/2022Piper SandlerInitiated CoverageOverweight$53.00High
5/16/2022GuggenheimBoost TargetNA$60.00N/A
5/12/2022SVB LeerinkReiterated RatingOutperformN/A
3/10/2022Credit Suisse GroupBoost TargetOutperform$50.00 ➝ $52.00High
3/10/2022Wells Fargo & CompanyBoost TargetOverweight$42.00 ➝ $53.00High
3/10/2022SVB LeerinkBoost TargetOutperform$47.00 ➝ $55.00Medium
2/11/2022BTIG ResearchInitiated CoverageBuy$62.00High
12/13/2021Royal Bank of CanadaInitiated CoverageOutperform$46.00Medium
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$42.00Low
12/8/2021SVB LeerinkBoost TargetOutperform$43.00 ➝ $47.00High
12/8/2021OppenheimerUpgradeMarket Perform ➝ Outperform$35.00 ➝ $50.00High
11/15/2021OppenheimerDowngradeOutperform ➝ Market Perform$35.00High
11/15/2021SVB LeerinkBoost TargetOutperform$34.00 ➝ $43.00High
11/12/2021Stifel NicolausInitiated CoverageBuy$45.00High
10/4/2021OppenheimerInitiated CoverageOutperform$35.00Medium
5/24/2021Stifel NicolausReiterated RatingBuyLow
5/14/2021Stifel NicolausReiterated RatingBuy$25.00N/A
4/13/2021Credit Suisse GroupInitiated CoverageOutperform$30.00N/A
4/13/2021SVB LeerinkInitiated CoverageOutperform$34.00N/A
4/13/2021Stifel NicolausInitiated CoverageBuy$25.00N/A
4/13/2021GuggenheimInitiated CoverageBuy$40.00N/A
4/6/2021Stifel NicolausInitiated CoverageBuy$25.00N/A
4/6/2021GuggenheimInitiated CoverageBuy$40.00N/A
4/6/2021SVB LeerinkInitiated CoverageOutperform$34.00N/A
4/6/2021Credit Suisse GroupInitiated CoverageOutperform$30.00N/A
2/9/2018Cantor FitzgeraldReiterated RatingHold$27.00Low
(Data available from 1/31/2018 forward)

News Sentiment Rating

0.72 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
7/4/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/3/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/2/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/2/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/1/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/1/2022
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/31/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/30/2023

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Prometheus Biosciences logo
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $114.77
Low: $112.98
High: $116.45

50 Day Range

MA: $96.21
Low: $36.06
High: $121.25

52 Week Range

Now: $114.77
Low: $21.50
High: $122.75

Volume

460,422 shs

Average Volume

505,617 shs

Market Capitalization

$4.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Prometheus Biosciences?

The following sell-side analysts have issued research reports on Prometheus Biosciences in the last twelve months: BTIG Research, Credit Suisse Group AG, Guggenheim, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for RXDX.

What is the current price target for Prometheus Biosciences?

10 Wall Street analysts have set twelve-month price targets for Prometheus Biosciences in the last year. Their average twelve-month price target is $107.80, suggesting a possible downside of 6.1%. BTIG Research has the highest price target set, predicting RXDX will reach $181.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $51.00 for Prometheus Biosciences in the next year.
View the latest price targets for RXDX.

What is the current consensus analyst rating for Prometheus Biosciences?

Prometheus Biosciences currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RXDX will outperform the market and that investors should add to their positions of Prometheus Biosciences.
View the latest ratings for RXDX.

What other companies compete with Prometheus Biosciences?

How do I contact Prometheus Biosciences' investor relations team?

Prometheus Biosciences' physical mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company's listed phone number is 858-422-4300 and its investor relations email address is [email protected] The official website for Prometheus Biosciences is ignyta.com. Learn More about contacing Prometheus Biosciences investor relations.